

necessary.

Claims 1-3, 5-6, 11, and 14-17 were rejected under 35 U.S.C. §112, first paragraph for lacking enablement for all hybridomas or monoclonal antibodies that bind to the AT1 subtype of the angiotensin II receptor. Applicant has canceled claims 1-3, 5-6, 11, and 14-17. Accordingly, it is respectfully requested that this rejection now be withdrawn.

Claims 1-7, 11, and 18 were rejected under 35 U.S.C. §102(a) as being anticipated by Barker, et al. (J.Mol. Endocrinol. 1993). As acknowledged by the Examiner, the submission of foreign priority papers obviates this rejection. Accordingly, it is respectfully requested that this rejection now be withdrawn.

Claims 1-7 were rejected under the judicially created doctrine of obviousness-type double patenting. Applicants have canceled claims 1-7. Accordingly, it is respectfully requested that the double patenting rejection now be withdrawn. For the reasons outlined in detail below, it is respectfully submitted that the pending claims are in condition for allowance.

New claims 20 and 21 have been added which depend from claims 18 and 19, respectively. There being no remaining prior art rejections against claims 18 and 19, it is submitted that claims 18 and 19, and claims 20 and 21 dependent therefrom, now be allowed.

An early allowance of all of pending claims 18-21 is earnestly solicited.

CONCLUSION

The above response and amendment are considered to place the application in condition for allowance. A prompt and favorable examination is respectfully requested.

Respectfully submitted,

**FAY, SHARPE, FAGAN,
MINNICH & McKEE, LLP**



Jay F. Moldovanyi, Reg. No. 29,678
Ann M. Skerry, Reg. No. 45,655
1100 Superior Avenue, 7th Floor
Cleveland, Ohio 44114-2518
216/861-5582

Application Serial No. 09/540,816
Filed March 31, 2000

**VERSION OF SPECIFICATION AND CLAIMS WITH
MARKINGS TO SHOW CHANGES MADE
February 4, 2003**

In the Specification:

On page 1, please amend the first full paragraph, as follows:

This application is a continuation of application Serial. No. 08/624,374 which was filed on March 27, 1996 [and still pending], now U.S. Patent No. 6,063,620. That application, in turn, is the entry into the National Phase of International Application No. PCT/GB 94/021100 which was filed on September 27, 1994.

In the Claims:

Please cancel claims 1-7, 11, and 14-17.

Please amend claims 18 and 19, as follows:

18. (Amended) A diagnostic test kit comprising a [labeled] monoclonal antibody attached to a detectable label, wherein said monoclonal [antibody] antibody binds specifically to a peptide having the amino acid sequence (SEQ ID. No. 1) H₂N--Glu--Asp--Gly--Ile--Lys--Arg--Ile--Gln--Asp--Asp----COOH.

19. (Amended) A diagnostic test kit comprising a labeled monoclonal antibody, wherein said monoclonal antibody binds to the AT₁ subtype of the angiotensin II receptor, the antibody being produced by a hybridoma cell line deposited at European Collection of Animal Cell Cultures, Porton Down, UK under
5 Accession No. 930720117.

20. (New) A diagnostic test kit according to claim 18, wherein said label includes a compound selected from the group consisting of radioisotopes, enzymes, and fluorescent compounds.

21. (New) A diagnostic test kit according to claim 19, wherein said label includes a compound selected from the group consisting of radioisotopes, enzymes, and fluorescent compounds.



Creation date: 01-14-2004
Indexing Officer: CPHAN - COUNG PHAN
Team: OIPEBackFileIndexing
Dossier: 09540816

Legal Date: 04-28-2003

No.	Doccode	Number of pages
1	SRNT	1

Total number of pages: 1

Remarks:

Order of re-scan issued on